RecruitingPhase 2Phase 3NCT06193889

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis

Sponsor

Kyverna Therapeutics

Enrollment

66 participants

Start Date

Aug 28, 2024

Study Type

INTERVENTIONAL

Conditions

Myasthenia Gravis Generalized Myasthenia Gravis

Summary

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called KYV-101, a drug called Standard lymphodepletion regimen, and others for people with generalized myasthenia gravis and myasthenia gravis. The study is currently recruiting participants at 22 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGStandard of Care Treatment

Standard of Care Medications Optional Crossover to receive KYV-101 treatment

DRUGStandard lymphodepletion regimen

Standard lymphodepletion regimen

BIOLOGICALKYV-101

Anti-CD19 CAR-T cell therapy

Locations(22)

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

University of California, Irvine

Orange, California, United States

Stanford University Medical Center

Palo Alto, California, United States

University of Miami

Miami, Florida, United States

Indiana University Health

Indianapolis, Indiana, United States

University of Missouri

Columbia, Missouri, United States

Oregon Health & Science University

Portland, Oregon, United States

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Houston Methodist Hospital

Houston, Texas, United States

Intermountain Medical Center

Murray, Utah, United States

Westmead Institute for Medical Research

Westmead, Australia

Hospital Israelita Albert Einstein

São Paulo, Brazil

Charite- Universitätsklinikum Berlin

Berlin, Germany

Universitätsklinikum der Ruhr-Universität Bochum

Bochum, Germany

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany

Medizinische Hochscule Hannover

Hanover, Germany

Friedrich-Schiller-Universität Jena

Jena, Germany

Universitätsklinik Magdeburg

Magdeburg, Germany

Technical University Munich, Klinikum Rechts der Isar

Munich, Germany

King's Faisal Specialist Hospital and Research Center

Riyadh, Kindom of Saudi Arabia, Saudi Arabia

Cambridge University Hospital, Addenbrooke's Hospital

Cambridge, United Kingdom

King's College Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06193889

Related Trials

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587145 locations

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT076737442 locations

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT069875394 locations

Capturing Key MG-symptoms Using Smartphone Recordings.

NCT067434902 locations